Brokerages Set Medtronic PLC (NYSE:MDT) Target Price at $107.80

Shares of Medtronic PLC (NYSE:MDT) have received a consensus recommendation of “Moderate Buy” from the twenty-six brokerages that are covering the company, Marketbeat Ratings reports. Eleven research analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $107.80.

A number of brokerages recently issued reports on MDT. UBS Group lowered their price target on shares of Medtronic from $104.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, April 22nd. Barclays increased their price target on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Evercore set a $106.00 price target on Medtronic and gave the company an “outperform” rating in a research note on Thursday, April 9th. Truist Financial cut their price target on Medtronic from $103.00 to $95.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Finally, CICC Research assumed coverage on Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating for the company.

Medtronic Price Performance

NYSE:MDT opened at $76.12 on Wednesday. Medtronic has a one year low of $74.40 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm has a market cap of $97.73 billion, a price-to-earnings ratio of 21.20, a PEG ratio of 1.83 and a beta of 0.62. The firm’s fifty day moving average is $84.76 and its two-hundred day moving average is $93.64.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic will post 5.57 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were given a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.7%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Medtronic

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Lodestone Wealth Management LLC purchased a new position in Medtronic in the 4th quarter worth approximately $27,000. Anfield Capital Management LLC lifted its stake in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares in the last quarter. Monetary Solutions Ltd purchased a new position in Medtronic in the 4th quarter worth approximately $27,000. Valley Wealth Managers Inc. purchased a new stake in Medtronic in the 3rd quarter valued at $29,000. Finally, Board of the Pension Protection Fund purchased a new stake in Medtronic in the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).